AnGes, Inc. Logo

AnGes, Inc.

Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.

4563 | T

Overview

Corporate Details

ISIN(s):
JP3127700007
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ七丁目7番15号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AnGes, Inc., founded in 1999, is a biopharmaceutical company dedicated to the research and development of gene-based medicines. The company focuses on becoming a global leader in genetic pharmaceuticals by developing innovative treatments that harness the power of genes. Its core pipeline includes Hepatocyte Growth Factor (HGF) gene therapy products for blood vessel regeneration, DNA vaccines based on plasmid DNA technology, and NF-kB decoy oligonucleotides. AnGes actively engages in clinical studies and forms global alliances and manufacturing collaborations to advance its therapeutic programs and make novel treatments accessible to patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 07:30
Registration Form
有価証券届出書(参照方式)
Japanese 244.5 KB
2025-08-13 06:50
Interim Report
確認書
Japanese 8.9 KB
2025-08-13 04:19
Interim Report
半期報告書-第27期(2025/01/01-2025/12/31)
Japanese 488.0 KB
2025-03-31 04:52
Post-Annual General Meeting Information
臨時報告書
Japanese 25.5 KB
2025-03-31 03:22
Governance Information
内部統制報告書-第26期(2024/01/01-2024/12/31)
Japanese 23.7 KB
2025-03-31 03:18
Registration Form
確認書
Japanese 8.9 KB
2025-03-31 03:17
Registration Form
有価証券報告書-第26期(2024/01/01-2024/12/31)
Japanese 1.5 MB
2024-09-03 06:05
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 203.2 KB
2024-08-30 09:06
Registration Form
有価証券届出書(参照方式)
Japanese 381.2 KB
2024-08-14 02:28
Interim Report
確認書
Japanese 8.9 KB
2024-08-14 02:27
Interim Report
半期報告書-第26期(2024/01/01-2024/12/31)
Japanese 725.7 KB
2024-05-14 02:27
Report Publication Announcement
確認書
Japanese 8.9 KB
2024-05-14 02:25
Quarterly Report
四半期報告書-第26期第1四半期(2024/01/01-2024/03/31)
Japanese 457.7 KB
2024-03-29 01:45
Post-Annual General Meeting Information
臨時報告書
Japanese 24.0 KB
2024-03-29 01:43
Governance Information
内部統制報告書-第25期(2023/01/01-2023/12/31)
Japanese 23.6 KB

Automate Your Workflow. Get a real-time feed of all AnGes, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AnGes, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AnGes, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ARS Pharmaceuticals, Inc. Logo
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America
SPRY
ARTELO BIOSCIENCES, INC. Logo
Develops lipid-signaling therapeutics for cancer, pain, anxiety, and depression.
United States of America
ARTL
Artiva Biotherapeutics, Inc. Logo
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America
ARTV
Ascelia Pharma Logo
Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.
Sweden
ACE
Ascendis Pharma A/S Logo
Biopharma using proprietary TransCon® tech to develop therapies for rare diseases & oncology.
United States of America
ASND
ASCENTAGE PHARMA GROUP INTERNATIONAL Logo
Biopharma developing small-molecule drugs for cancer, HBV, and age-related diseases.
United States of America
AAPG
Specializes in hormone drugs for OB/GYN, urology, internal medicine, and animal health.
Japan
4886
Aspire Biopharma Holdings, Inc. Logo
Developing a nano-platform for rapid, sublingual delivery of reformulated medications.
United States of America
ASBP
ASSEMBLY BIOSCIENCES, INC. Logo
Clinical-stage biopharma developing small-molecule antivirals for herpes, HBV, and HDV.
United States of America
ASMB
Assertio Holdings, Inc. Logo
Offers branded prescription drugs for neurology, pain, and CNS to US patients.
United States of America
ASRT

Talk to a Data Expert

Have a question? We'll get back to you promptly.